Sitravatinib malate(Synonyms: MGCD516 malate; MG-516 malate)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Sitravatinib malate (Synonyms: MGCD516 malate; MG-516 malate)

Sitravatinib malate (MGCD516 malate) 是一种有口服活性的受体酪氨酸激酶 (RTK) 抑制剂。抑制 Axl,MER,VEGFR3,VEGFR2,VEGFR1,KIT,FLT3,DDR2,DDR1,TRKA,和 TRKB,IC50 分别为 1.5 nM,2 nM,2 nM,5 nM,6 nM,6 nM,8 nM,0.5 nM,29 nM,5 nM,和 9 nM。Sitravatinib malate 单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。

Sitravatinib malate(Synonyms: MGCD516 malate; MG-516 malate)

Sitravatinib malate Chemical Structure

CAS No. : 2244864-88-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Sitravatinib malate 的其他形式现货产品:

Sitravatinib

生物活性

Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively[1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment[2].

IC50 & Target[1]

VEGFR1

6 nM (IC50)

VEGFR2

5 nM (IC50)

VEGFR3

2 nM (IC50)

TrkA

5 nM (IC50)

TrkB

9 nM (IC50)

DDR1

29 nM (IC50)

DDR2

0.5 nM (IC50)

Axl

1.5 nM (IC50)

MER

2 nM (IC50)

KIT

6 nM (IC50)

FLT3

8 nM (IC50)

体外研究
(In Vitro)

Sitravatinib (0.01 nM-10 μM; 14 days) reduces colony formation in a dose-dependent manner in KLN205 and E0771 cell lines[2].
Sitravatinib (0.001-10 μM; 5 days) inhibits tumor cell viability with IC50s of approximately 1 μM in KLN205, E0771 and CT1B-A5 cell lines[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: KLN205, E0771, CT1B-A5 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 5 days
Result: Inhibited KLN205, E0771, CT1B-A5 cells with IC50s of approximately 1 μM.

体内研究
(In Vivo)

Sitravatinib (20 mg/kg; p.o.; once per day for 6 days) significantly inhibits tumor progression and induces tumor regression in C57BL/6 mice bearing CT1B-A5 cells model[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6-week-old C57BL/6 mice (bearing CT1B-A5 cells)[2]
Dosage: 20 mg/kg
Administration: Oral administration; once per day for 6 days
Result: Significantly inhibited tumor progression and induced tumor regression.

Clinical Trial

分子量

763.76

Formula

C37H35F2N5O9S

CAS 号

2244864-88-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109.

    [2]. Du W, et al. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018 Nov 2;3(21). pii: 124184.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务